Sector Expert: Yi Chen

Rodman & Renshaw



Recent Quotes

"INO's Zika virus vaccine success further validates the SynCon platform; we reiterate our Buy rating."

— Yi Chen, H.C. Wainwright & Co. (2/18/16)
more >

"The FDA cleared the clinical trial of INO's MERS vaccine, GLS-5300."

— Yi Chen, H.C. Wainwright & Co. (11/20/15)
more >

"INO's VGX-3100 could present a safe and non-surgical therapeutic option for CIN2/3."

— Yi Chen, H.C. Wainwright & Co. (9/22/15)
more >

"INO's cash balance should provide a runway to the end of 2018."

— Yi Chen, H.C. Wainwright & Co. (8/11/15)
more >

"INO announced a collaboration with the EORTC to evaluate INO-3112 for cervical cancer."

— Yi Chen, H.C. Wainwright & Co. (7/24/15)
more >

"INO initiated a Phase 1 trial to evaluate INO-4212 for Ebola."

— Yi Chen, H.C. Wainwright & Co. (5/13/15)
more >

"INO initiated a Phase 1 trial in chronic hepatitis B patients."

— Yi Chen, H.C. Wainwright & Co. (4/22/15)
more >

"We view DARPA's grant as a validation of INO's technology platform."

— Yi Chen, H.C. Wainwright & Co. (4/9/15)
more >



Due to permission requirements, not all quotes are shown.